<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6753013 - Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_4ff636b3d23669b7103f3b3a3a18b4cd/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_4ff636b3d23669b7103f3b3a3a18b4cd__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical"><meta name="DC.contributor" content="Erik Didriksen" scheme="inventor"><meta name="DC.contributor" content="Gert HÃ¸y" scheme="inventor"><meta name="DC.contributor" content="Leo Pharmaceutical Products, Ltd. A/S" scheme="assignee"><meta name="DC.date" content="2000-1-27" scheme="dateSubmitted"><meta name="DC.description" content="A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1. The composition can also have at least one solvent component C, where component C is compounds of the general formula R3 (OCH2C(R1)H)xOR2 (I), wherein x is in the range of 2-60, R1 in each of the x units independently is H or CH3, R2 is straight chain or branched C1-20alkyl or benzoyl, and R3 is H or phenylcarbonyloxy; di-(straight or branched)-C4-10alkyl esters of C4-C8dicarboxylic acids; straight or branched C12-18-alkyl benzoates; straight or branched C2-4-alkyl esters of straight or branched C10-18-alkanoic or -alkenoic acids; propylenglycol diesters with C8-14-alkanoic acids; and branched primary C18-24alkanols."><meta name="DC.date" content="2004-6-22" scheme="issued"><meta name="DC.relation" content="EP:0129003:A2" scheme="references"><meta name="DC.relation" content="EP:0544391:A1" scheme="references"><meta name="DC.relation" content="US:4569935" scheme="references"><meta name="DC.relation" content="US:4794106" scheme="references"><meta name="DC.relation" content="US:4981845" scheme="references"><meta name="DC.relation" content="US:5087620" scheme="references"><meta name="DC.relation" content="US:5827520" scheme="references"><meta name="DC.relation" content="US:5854246" scheme="references"><meta name="DC.relation" content="US:5886038" scheme="references"><meta name="DC.relation" content="US:5990100" scheme="references"><meta name="DC.relation" content="WO:1991012807:A1" scheme="references"><meta name="DC.relation" content="WO:1994014453:A1" scheme="references"><meta name="DC.relation" content="WO:1994015912:A1" scheme="references"><meta name="citation_reference" content="&quot;Database STN Intern. File Caplus [On line]; Glade C P et al: Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of&quot; retrieved from CAPLUS, accession No. 1996:599855. Database accession No. 125:266250 XP002900974 abstract * BR. J. Dermatol., vol. 135, No. 3, 1996, pp. 379-384."><meta name="citation_reference" content="Bazek et al., Nouv. Dermatol., vol. 13, No. 10, pp. 746-751 (1994) (with English translation)."><meta name="citation_reference" content="CAPlus AN: 1985:27554 English abstract of Veverka, CS 214078, 1982.*"><meta name="citation_reference" content="Gennaro Remington&#39;s Pharmaceutical Sciences, 18th ed., p. 1310.*"><meta name="citation_reference" content="Kragballe et al., British Journal of Dermatology, vol. 139, pp. 649-654 (1998)."><meta name="citation_reference" content="Richards et al., J. Am. Acad Dermatol., vol. 41, No. 4, pp. 581-583 (Oct. 1999)."><meta name="citation_reference" content="Ruzick et al.., British Journal of Dermatology 1998; 139: 254-258.*"><meta name="citation_reference" content="Ruzicka et al: &quot;Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks&#39;treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, doucle-blind, randomized study&quot; British Journal of Dermatology, vol. 138, 1998, pp. 254-258, XP002900975 pp. 257."><meta name="citation_patent_number" content="US:6753013"><meta name="citation_patent_application_number" content="US:09/959,367"><link rel="canonical" href="http://www.google.com/patents/US6753013"/><meta property="og:url" content="http://www.google.com/patents/US6753013"/><meta name="title" content="Patent US6753013 - Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical"/><meta name="description" content="A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1. The composition can also have at least one solvent component C, where component C is compounds of the general formula R3 (OCH2C(R1)H)xOR2 (I), wherein x is in the range of 2-60, R1 in each of the x units independently is H or CH3, R2 is straight chain or branched C1-20alkyl or benzoyl, and R3 is H or phenylcarbonyloxy; di-(straight or branched)-C4-10alkyl esters of C4-C8dicarboxylic acids; straight or branched C12-18-alkyl benzoates; straight or branched C2-4-alkyl esters of straight or branched C10-18-alkanoic or -alkenoic acids; propylenglycol diesters with C8-14-alkanoic acids; and branched primary C18-24alkanols."/><meta property="og:title" content="Patent US6753013 - Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("9OPoU7iYMZawyASRvICABA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407291699.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("LUX"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("9OPoU7iYMZawyASRvICABA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407291699.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("LUX"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6753013?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6753013"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=DRVnBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6753013&amp;usg=AFQjCNGpETFPCT-kvdO4_uHodc1ISItKIw" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6753013.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6753013.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6753013" style="display:none"><span itemprop="description">A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between...</span><span itemprop="url">http://www.google.com/patents/US6753013?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6753013 - Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6753013 - Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical" title="Patent US6753013 - Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6753013 B1</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 09/959,367</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/DK2000/000033</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jun 22, 2004</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jan 27, 2000</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Apr 23, 1999</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2370565A1">CA2370565A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2370565C">CA2370565C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1173703C">CN1173703C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1351499A">CN1351499A</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1178808A1">EP1178808A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1178808B1">EP1178808B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2450043A1">EP2450043A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2455083A1">EP2455083A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2455083B1">EP2455083B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2000064450A1">WO2000064450A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">09959367, </span><span class="patent-bibdata-value">959367, </span><span class="patent-bibdata-value">PCT/2000/33, </span><span class="patent-bibdata-value">PCT/DK/0/000033, </span><span class="patent-bibdata-value">PCT/DK/0/00033, </span><span class="patent-bibdata-value">PCT/DK/2000/000033, </span><span class="patent-bibdata-value">PCT/DK/2000/00033, </span><span class="patent-bibdata-value">PCT/DK0/000033, </span><span class="patent-bibdata-value">PCT/DK0/00033, </span><span class="patent-bibdata-value">PCT/DK0000033, </span><span class="patent-bibdata-value">PCT/DK000033, </span><span class="patent-bibdata-value">PCT/DK2000/000033, </span><span class="patent-bibdata-value">PCT/DK2000/00033, </span><span class="patent-bibdata-value">PCT/DK2000000033, </span><span class="patent-bibdata-value">PCT/DK200000033, </span><span class="patent-bibdata-value">US 6753013 B1, </span><span class="patent-bibdata-value">US 6753013B1, </span><span class="patent-bibdata-value">US-B1-6753013, </span><span class="patent-bibdata-value">US6753013 B1, </span><span class="patent-bibdata-value">US6753013B1</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Erik+Didriksen%22">Erik Didriksen</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Gert+H%C3%B8y%22">Gert HÃ¸y</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Leo+Pharmaceutical+Products,+Ltd.+A/S%22">Leo Pharmaceutical Products, Ltd. A/S</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6753013.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6753013.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6753013.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (13),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (8),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (18),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (40),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (7)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6753013&usg=AFQjCNEYDvNrIr08FX7-TksSQizsfUfVaQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6753013&usg=AFQjCNFGV-iHJAtEJZdyyojCdwoAW6Wz_w">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6753013B1%26KC%3DB1%26FT%3DD&usg=AFQjCNGSacjGZ2sSrIJxbmK9DVcKTBnhrA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129200254" lang="EN" load-source="ifi">Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical</invention-title></span><br><span class="patent-number">US 6753013 B1</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA50685196" lang="EN" load-source="patent-office"> <div class="abstract">A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1. The composition can also have at least one solvent component C, where component C is compounds of the general formula R<sup>3 </sup>(OCH<sub>2</sub>C(R<sup>1</sup>)H)<sub>x</sub>OR<sup>2 </sup>(I), wherein x is in the range of 2-60, R<sup>1 </sup>in each of the x units independently is H or CH<sub>3</sub>, R<sup>2 </sup>is straight chain or branched C<sub>1-20</sub>alkyl or benzoyl, and R<sup>3 </sup>is H or phenylcarbonyloxy; di-(straight or branched)-C<sub>4-10</sub>alkyl esters of C<sub>4</sub>-C<sub>8</sub>dicarboxylic acids; straight or branched C<sub>12-18</sub>-alkyl benzoates; straight or branched C<sub>2-4</sub>-alkyl esters of straight or branched C<sub>10-18</sub>-alkanoic or -alkenoic acids; propylenglycol diesters with C<sub>8-14</sub>-alkanoic acids; and branched primary C<sub>18-24</sub>alkanols.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(4)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6753013B1/US06753013-20040622-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6753013B1/US06753013-20040622-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6753013B1/US06753013-20040622-D00002.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6753013B1/US06753013-20040622-D00002.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6753013B1/US06753013-20040622-D00003.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6753013B1/US06753013-20040622-D00003.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6753013B1/US06753013-20040622-D00004.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6753013B1/US06753013-20040622-D00004.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(23)</span></span></div><div class="patent-text"><div mxw-id="PCLM8692999" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6753013-B1-CLM-00001" class="claim">
      <div class="claim-text">1. A pharmaceutical composition for dermal use, said composition comprising:</div>
      <div class="claim-text">a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue selected from the group consisting of seocalcitol, calcipotriol, calcitriol, tacalcitol, maxacalcitol, paricalcitol, falecalcitriol, 1Î±,24S-dihydroxy-vitamin D2, 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene and mixtures thereof; and </div>
      <div class="claim-text">a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1; and </div>
      <div class="claim-text">at least one solvent component C selected from the group consisting of: </div>
      <div class="claim-text">(i) compounds of the general formula R<sup>3</sup>(OCH<sub>2</sub>C(R<sup>1</sup>)H)<sub>x</sub>OR<sup>2 </sup>(I) wherein x is in the range of 2-60, R<sup>1 </sup>in each of the x units independently is H or CH<sub>3</sub>, R<sup>2 </sup>is straight chain or branched C<sub>1-20</sub>alkyl or benzoyl, and R<sup>3 </sup>is H or phenylcarbonyloxy; </div>
      <div class="claim-text">(ii) di-(straight or branched)-C<sub>4-10</sub>alkyl esters of C<sub>4</sub>-C<sub>8 </sub>dicarboxylic acids; </div>
      <div class="claim-text">(iii) straight or branched C<sub>12-18</sub>-alkyl benzoates; </div>
      <div class="claim-text">(iv) straight or branched C<sub>2-4</sub>-alkyl esters of straight or branched C<sub>10-18</sub>-alkanoic or -alkenoic acids; </div>
      <div class="claim-text">(v) propylenglycol diesters with C<sub>8-14</sub>-alkanoic acids; and </div>
      <div class="claim-text">(vi) branched primary C<sub>18-24 </sub>alkanols. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" id="US-6753013-B1-CLM-00002" class="claim">
      <div class="claim-text">2. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref>, wherein said vitamin D analogue is selected from the group consisting of calcipotriol, calcitriol, tacalcitol, maxacalcitol, 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene, and mixtures thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" id="US-6753013-B1-CLM-00003" class="claim">
      <div class="claim-text">3. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or <claim-ref idref="US-6753013-B1-CLM-00002">2</claim-ref>, wherein the vitamin D analogue is effective against psoriasis and related disorders of the skin in humans and other mammals.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" id="US-6753013-B1-CLM-00004" class="claim">
      <div class="claim-text">4. The composition according to <claim-ref idref="US-6753013-B1-CLM-00003">claim 3</claim-ref>, wherein said vitamin D analogue is calcipotriol or its hydrate thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" id="US-6753013-B1-CLM-00005" class="claim">
      <div class="claim-text">5. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or <claim-ref idref="US-6753013-B1-CLM-00002">2</claim-ref>, wherein said corticosteroid is selected from the group consisting of Betamethasone, Clobetasol, Clobetasone, Desoximethasone, Diflucortolon, Diflorasone, Fluocinonid, Flumethasone, Fluocinolon, Fluticasone, Fluprednidene, Halcinonide, Hydrocortisone, Momethasone, Triamcinolon, and pharmaceutically acceptable esters and acetonides as well as mixtures thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" id="US-6753013-B1-CLM-00006" class="claim">
      <div class="claim-text">6. The composition according to <claim-ref idref="US-6753013-B1-CLM-00005">claim 5</claim-ref>, wherein said esters or acetonides are selected from the group consisting of 17-valerate, 17-propionate, 17,21-dipropionate, acetonide, acetonide-21-N-benzoyl-2-methyl-Î²-alaninate, acetonide-21-(3,3-dimethylbutyrate) and 17-butyrate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" id="US-6753013-B1-CLM-00007" class="claim">
      <div class="claim-text">7. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or <claim-ref idref="US-6753013-B1-CLM-00002">2</claim-ref>, wherein said corticosteroid is selected from the group consisting of group I topical steroid, group II topical steroid and group III topical steroid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" id="US-6753013-B1-CLM-00008" class="claim">
      <div class="claim-text">8. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or <claim-ref idref="US-6753013-B1-CLM-00002">2</claim-ref>, wherein said composition is in the form of a non-aqueous composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" id="US-6753013-B1-CLM-00009" class="claim">
      <div class="claim-text">9. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or <claim-ref idref="US-6753013-B1-CLM-00002">2</claim-ref>, wherein said composition is in the form of a non-aqueous composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" id="US-6753013-B1-CLM-00010" class="claim">
      <div class="claim-text">10. The composition according to <claim-ref idref="US-6753013-B1-CLM-00009">claim 9</claim-ref>, wherein said composition is an ointment.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" id="US-6753013-B1-CLM-00011" class="claim">
      <div class="claim-text">11. The composition according to <claim-ref idref="US-6753013-B1-CLM-00010">claim 10</claim-ref>, wherein said composition has the following composition:</div>
      <div class="claim-text">
        <tables> <table frame="none" colsep="0" rowsep="0"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="28pt" align="left"> </colspec> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="56pt" align="left"> </colspec> <thead> <row> <entry> </entry> <entry namest="offset" nameend="2" align="center" rowsep="1"> </entry> </row> </thead> <tbody valign="top"> <row> <entry> </entry> <entry>Betamethasone</entry> <entry>0.5 mg</entry> </row> <row> <entry> </entry> <entry>Calcipotriol</entry> <entry>â50 Î¼g</entry> </row> <row> <entry> </entry> <entry>Paraffin, Liquid</entry> <entry>â30 mg</entry> </row> <row> <entry> </entry> <entry>Polyoxypropylene-15-Stearyl Ether</entry> <entry>â50 mg</entry> </row> <row> <entry> </entry> <entry>Î±-Tocopherol</entry> <entry>â20 Î¼g</entry> </row> <row> <entry> </entry> <entry>White Soft Paraffin to make</entry> <entry>ââ1 g.</entry> </row> <row> <entry> </entry> <entry namest="offset" nameend="2" align="center" rowsep="1"> </entry> </row> </tbody> </tgroup> </table> </tables> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" id="US-6753013-B1-CLM-00012" class="claim">
      <div class="claim-text">12. A lotion comprising the composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or <claim-ref idref="US-6753013-B1-CLM-00002">2</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" id="US-6753013-B1-CLM-00013" class="claim">
      <div class="claim-text">13. The composition according to <claim-ref idref="US-6753013-B1-CLM-00012">claim 12</claim-ref>, said composition having the following composition:</div>
      <div class="claim-text">
        <tables> <table frame="none" colsep="0" rowsep="0"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="28pt" align="left"> </colspec> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="56pt" align="left"> </colspec> <thead> <row> <entry> </entry> <entry namest="offset" nameend="2" align="center" rowsep="1"> </entry> </row> </thead> <tbody valign="top"> <row> <entry> </entry> <entry>Betamethasone</entry> <entry>â0.5 mg</entry> </row> <row> <entry> </entry> <entry>Calcipotriol (as Hydrate 52.2 Î¼g)</entry> <entry>â50 Î¼g</entry> </row> <row> <entry> </entry> <entry>Disodium Phosphate Dihydrate</entry> <entry>â2.5 mg</entry> </row> <row> <entry> </entry> <entry>Diazolidinyl Urea</entry> <entry>â3 mg</entry> </row> <row> <entry> </entry> <entry>Polyoxypropylene-15-Stearyl Ether</entry> <entry>â50 mg</entry> </row> <row> <entry> </entry> <entry>Isohexadecan</entry> <entry>200 mg</entry> </row> <row> <entry> </entry> <entry>Polyoxyethylene-2-Stearyl Ether</entry> <entry>â30 mg</entry> </row> <row> <entry> </entry> <entry>Water, purified to make</entry> <entry>â1 g.</entry> </row> <row> <entry> </entry> <entry namest="offset" nameend="2" align="center" rowsep="1"> </entry> </row> </tbody> </tgroup> </table> </tables> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" id="US-6753013-B1-CLM-00014" class="claim">
      <div class="claim-text">14. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref>, wherein said component C is selected from the group consisting of a compound of the general formula H(OCH<sub>2</sub>C(R<sup>1</sup>)H)<sub>x</sub>OR<sup>2 </sup>(II) and mixtures thereof, wherein where R<sup>1</sup>, x, and R<sup>2 </sup>are as defined in <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" id="US-6753013-B1-CLM-00015" class="claim">
      <div class="claim-text">15. The composition according to <claim-ref idref="US-6753013-B1-CLM-00014">claim 14</claim-ref>, wherein where R<sup>1 </sup>in the general formula is CH<sub>3</sub>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" id="US-6753013-B1-CLM-00016" class="claim">
      <div class="claim-text">16. The composition according to <claim-ref idref="US-6753013-B1-CLM-00014">claim 14</claim-ref>, wherein said component C is polyoxypropylene-15-stearyl ether.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" id="US-6753013-B1-CLM-00017" class="claim">
      <div class="claim-text">17. The composition according to <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or containing 0.001-0.25 mg/g or ml of said component A and 0.005-0.1% w/w of said component B.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" id="US-6753013-B1-CLM-00018" class="claim">
      <div class="claim-text">18. A method of treating psoriasis, sebopsoriasis or seborrhoic dermatitis, the method comprising</div>
      <div class="claim-text">topically administering an effective amount of the composition of <claim-ref idref="US-6753013-B1-CLM-00001">claim 1</claim-ref> or <claim-ref idref="US-6753013-B1-CLM-00002">2</claim-ref>, to a patient in need of such treatment. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" id="US-6753013-B1-CLM-00019" class="claim">
      <div class="claim-text">19. The method of <claim-ref idref="US-6753013-B1-CLM-00018">claim 18</claim-ref> comprising topical administration once or twice daily of a medically sufficient dosage of said composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" id="US-6753013-B1-CLM-00020" class="claim">
      <div class="claim-text">20. The method of <claim-ref idref="US-6753013-B1-CLM-00018">claim 18</claim-ref>, wherein application of the composition results in a higher efficacy in the treatment of psoriasis, sebopsoriasis or seborrhoic dermatitis than the efficacy attainable when using any composition comprising said components A or B alone.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" id="US-6753013-B1-CLM-00021" class="claim">
      <div class="claim-text">21. The method of <claim-ref idref="US-6753013-B1-CLM-00018">claim 18</claim-ref>, wherein the efficacy of said treatment is measured, and said efficacy is measured as a percentage change in Psoriasis Area and Severity Index score.</div>
    </div>
    </div> <div class="claim"> <div num="22" id="US-6753013-B1-CLM-00022" class="claim">
      <div class="claim-text">22. A pharmaceutical composition comprising:</div>
      <div class="claim-text">a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue selected from the group consisting of seocalcitol, calcipotriol, calcitriol, tacalcitol, maxacalcitol, paricalcitol, falecalcitriol, 1Î±,24S-dihydroxy-vitamin D2, 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene and mixtures thereof; and </div>
      <div class="claim-text">a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1; and </div>
      <div class="claim-text">at least one solvent component C selected from the group consisting of: </div>
      <div class="claim-text">(i) compounds of the general formula R<sup>3</sup>(OCH<sub>2</sub>C(R<sup>1</sup>)H)<sub>x</sub>OR<sup>2 </sup>(I) wherein x is in the range of 2-60, R<sup>1 </sup>in each of the x units independently is H or CH<sub>3</sub>, R<sup>2 </sup>is straight chain or branched C<sub>1-20</sub>alkyl or benzoyl, and R<sup>3 </sup>is H or phenylcarbonyloxy; </div>
      <div class="claim-text">(ii) straight or branched C<sub>2-4</sub>-alkyl esters of straight or branched C<sub>10-18</sub>-alkanoic or -alkenoic acids; </div>
      <div class="claim-text">(iii) propylenglycol diesters with C<sub>8-14</sub>-alkanoic acids; and (iv) branched primary C<sub>18-24 </sub>alkanols; </div>
      <div class="claim-text">wherein said pharmaceutical composition is storage stable, non-aqueous and in a single container. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="23" id="US-6753013-B1-CLM-00023" class="claim">
      <div class="claim-text">23. The pharmaceutical composition of <claim-ref idref="US-6753013-B1-CLM-00022">claim 22</claim-ref>, wherein said pharmaceutical composition is stable when stored at 40Â° C. for 3 months.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES54200722" lang="EN" load-source="patent-office" class="description">
    <p>This application is the National Phase of International Application PCT/DK00/00033 filed Jan. 27, 2000 which designated the U.S. and that International Application</p>
    <heading>FIELD OF THE INVENTION</heading> <p>The present invention concerns pharmaceutical compositions for dermal use which contain at least one vitamin D or vitamin D analogue and at least one corticosteroid. More specifically, the invention relates to pharmaceutical compositions containing two or more pharmacologically active compounds which have low compatibility with respect to the pH value of optimum stability, preferably, said pharmacologically active compounds are at least one vitamin D analogue and at least one corticosteroid.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>In the treatment of a number of conditions using dermal application, e.g. in the art treatment of psoriasis, it is often indicated to employ a combination treatment incorporating two or even more different pharmacologically active compounds. Thus, in the treatment of e.g. psoriasis, it is common to use a combination treatment involving a steroid compound, such as a corticosteroid compound, and a vitamin D analogue such as calcipotriol, and where each of the active compounds are formulated in separate preparations.</p>
    <p>Until now a topical pharmaceutical composition comprising a combination of a vitamin D analogue and a topical steroid has not been described. Moreover, these two types of compounds often have optimum stability values of pH that differ significantly from one another making it non-obvious to attempt to prepare a topical pharmaceutical preparation containing a steroid compound together with a vitamin D analogue. U.S. Pat. No. 5,565,462 relates to topical pharmaceutical compositions containing certain xanthine compounds, and where said compositions may additionally contain active compounds, such as steroids and vitamin D and its derivatives. However, there is no disclosure of a topical composition containing both a steroid and a vitamin D or vitamin D analogue or derivative, nor is there any description of a method of preparing such a composition.</p>
    <p>The following example describes the difficulties encountered when the skilled person wishes to prepare a combination composition for topical use comprising both a vitamin D or a vitamin D analogue or derivative and a topical steroid: The vitamin D analogue calcipotriol, as well as other examples of vitamin D analogues, requires a pH value above 8 for maximum stability, whereas corticosteroids such as Betamethasone (9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione) require pH values in the range of 4-6 for maximum stability. Since the base auxiliary materials and additives traditionally used in preparing topical formulations, such as creams and/or ointments, involve having some kind of acid or alkaline nature or reaction ability, it has therefore hitherto not been possible to combine the two active compounds in one single formulation while maintaining good stability of the active compounds.</p>
    <p>Consequently, physicians have had to resort to letting patients under this type of two-component regimen perform sequential application of two creams/ointments, each containing one of the compounds formulated at its maximum stability pH. This may lead to incompatibility of the preparations so that patients must, e.g., apply one cream/ointment in the morning and the other in the evening. Needless to say, patient compliance as well as correct administration dosage is a problem under such circumstances. Richards, H. L. et al. report in <i>J Am Acad Dermatol </i>1999 October; 41(4):581-3 on a study of patients with psoriasis and their compliance with medication. They report that poor compliance with treatment advice in chronic conditions, such as psoriasis, represents a major challenge to health care professionals: Thirty-nine percent of participants reported that they did not comply with the treatment regimen recommended. The noncompliant group had a higher self-rated severity of psoriasis, were younger, and had a younger age at onset than those who were compliant. The noncompliant group reported that psoriasis had a greater impact on daily life.</p>
    <p>It is therefore an object of the present invention to provide a pharmaceutical composition for dermal use where said composition alleviates the inconveniences of a two-component or multi-component regimen for the treatment of psoriasis and other inflammatory skin diseases including nail diseases. The provision of said composition will result in a substantial improvement in quality of life for a large population of psoriasis patients, especially the noncompliant group having a higher self-rated severity of psoriasis, being younger, and having a younger age at onset than those who are compliant.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>In order to solve the above mentioned problems, the invention provides a pharmaceutical composition for dermal use, said composition comprising a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue and a second pharmacologically active component B consisting of at least one corticosteroid.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>As a first pharmacologically active component A it is preferred to use a compound selected from the group consisting of seocalcitol; calcipotriol; calcitriol; tacalcitol, maxacalcitol; paricalcitol; falecalcitriol; 1Î±, 24S-dihydroxy-vitamin D2; and 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene, as well as mixtures thereof.</p>
    <p>More preferred are vitamin D analogues selected from the group consisting of calcipotriol, calcitriol, tacalcitol, maxacalcitol, and 1(S),3(R)-dihydroxy-20(R)-[((3(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene as well as mixtures thereof. Synthetic vitamin D analogues are more preferred in the compositions according to the invention than naturally occurring vitamin D's or vitamin D derivatives, since the therapeutic effects of the latter may be less selective for the treatment of skin diseases, such as psoriasis.</p>
    <p>Further non-limiting examples of vitamin D compounds constituting the first pharmacologically active component A are:</p>
    <p>alphacalcidol;</p>
    <p>1Î±-hydroxy-vitamin D2;</p>
    <p>1Î±-hydroxy-vitamin D5;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5-ethyl-5-hydroxy-1-heptyl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(6-hydroxy-6-methyl-1-heptyl)-9,10-secopregna-5(2),7(E)-10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(6-hydroxy-6-methylhept-1(E)-ene-1-yl-9,10)-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(6-ethyl-6hydroxy-1-octyl)-9,10)-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(7-hydroxy-7-methyl-1-octyl)-9,10)-secopregna-5(2),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(7-hydroxy-7-methyloct-1(E)-en-1-yl-9,10)-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(6â²-methyl-1â²-heptyl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-(5â²-hydroxy-5â²-methyl-1â²-hexyloxy)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4â²-hydroxy-4â²ethyl-1â²-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(6â²-hydroxy-1â²-hexyloxy-9,10-seco-pregna-5(Z),7(E),10(19 )-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5â²-hydroxy-5â²-ethyl-1â²-heptyloxy)-9,10-seco-pregna-5(,7(E),10,19-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5â²-hydroxy-5â²-methyl-1â²-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5â²-methyl-1â²-hexyloxy)-9,10-seco-pregna-5(Z),7(E),<sub>10</sub>(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4â²-hydroxy4â²-(1 â³-propyl)-1â²-heptyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4â²-hydroxy-4â²-methyl-1â²-pentyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3â²-hydroxy-3â²-methyl-1â²-butyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-(4-hydroxy-4-methyl-1-pentyl)-9,10-secopregna-(5Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-(5-ethyl-5-hydroxy-1-hept-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-(5-ethyl-5-hydroxy-hept-1(E)-en-1-yl),9,10-secopregna-5(2),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-(5â²-hydroxy-1â²-methyl-hexa-1â²(E),3â²(E)-dien-1â²-yl)-9,10-secopregna-5(2),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-(5â²-ethyl-5â²hydroxy-hepta-1â²(E),3â²(E)-dien-1â²-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-(6â²-hydroxy-hexa-1â²(E),3â²(E)-dien-1â²-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-(5â²-cyclopropyl-5â²-hydroxy-penta-1â²(E),3â²(E)-dien-1â²-yl)-9,10-secopregna-5(Z)-7(E),10,19-triene (5â²(R) and 5â²(S) isomers);</p>
    <p>1(S),3(R)-Dihydroxy-20-(6â²-hydroxy-6â²-methyl-hepta-1â²(E),3â³(E)-dien-1â²-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3-(2-hydroxy-2-pentyl)-phenylmethoxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3-(3hydroxy-3-propyl)-phenylmethoxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4-hydroxy-4-methyl-1-pentyloxymethyl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4-hydroxy-4-methyl-1-pent-2-ynyloxymethyl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4-hydroxy-4-trifluoromethyl-5,5,5-trifluoro-1-pent-2-ynyloxymethyl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-[3-(2-hydroxy-2-propyl)-phenoxymethyl]-9,10seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3-hydroxy-3ethyl-1-pentylthiomethyl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3-hydroxy-3-ethyl-1-pentylsulphonylmethyl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3-((1-hydroxy-1-methyl)ethyl)phenylthiomethyl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3,3-difluoro-4-hydroxy-4-methyl-1-pentyloxymethyl)-9,10-seco-pregna-5(Z)-7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(6â²-ethyl-6â²-hydroxy-oct-1â²-yn-1â²-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(7â²-ethyl-7â²-hydroxy-non-1â²-yn-1â²-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(1,5-dihydroxy-5-ethyl-2-heptyn-1-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene; isomer A;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5-ethyl-5-hydroxy-1-methoxy-2-heptyn-1-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene; isomer A;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(1-ethoxy-5-ethyl-5-hydroxy-2-heptyn-1-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene; isomer A;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(1-methoxy-4-hydroxy-4-ethyl-2-hexyn-1-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene; isomer A;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(1-ethoxy-4-hydroxy-4-ethyl-2-hexyn-1-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene; isomer A;</p>
    <p>1(S),3(R)-Dihydroxy-20-(4-ethyl-4-hydroxy1-hexyn-1-yl)-9,10-seco-pregna-5(Z),7(E)-10(19)17(20)(Z)-tetraene;</p>
    <p>1(S),3(R)-Dihydroxy-20-(5-ethyl-5-hydroxy-1-heptyn-1-yl)-9,10-seco-pregna-5(Z),7(E)-10(19),17(20)(Z)-tetraene;</p>
    <p>1(S),3(R)-Dihydroxy-20-(6-ethyl-6-hydroxy-1-octyn-1-yl)-9,10-seco-pregna-5(Z),7(E),10(19),17(20)(Z)-tetraene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5-ethyl-4,4-difluoro-5-hydroxy-heptyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S)3(R)-Dihydroxy-20(R)-(4,4-dichloro-5-hydroxy-5-methyl-hexyloxy)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4,4-difluoro-5-hydroxy-5-methyl-hexyloxy)-9,10-seco-pregna-5(Z),7(E)-10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4-fluoro-4-methyl-pentyl-oxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4-ethyl-4-fluoro-hexyl-oxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5-fluoro-5methyl-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R),20(S)-Trihydroxy-20-(4-ethyl-4-hydroxy-1-hexyl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-methoxy-20-(4-ethyl-4-hydroxy-1-hexyl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-ethoxy-20-(4-ethyl-4-hydroxy-1-hexyl)-9,10-secopregna-5(Z),7(E),10(19)-triene;</p>
    <p>1 (S),3(R)-Dihydroxy-20(S)-[3-(2-hydroxy-2-methyl-1-propoxy)-prop-1E-en-1-yl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(4-ethyl-4-hydroxy-1-hexylthio)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-[5-methyl-5-hydroxy-1-hexylthio]-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-[3-(1-methyl-1-hydroxyethyl)benzylthio]-9,10-seco-pregna-5(Z),7E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3-methyl-3-hydroxy-1 butylthio)-9,10-seco-pregna-5(Z)-7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5-ethyl-5-hydroxy-hept-1(E)-en-3-yn-1-yl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>24-oxo-1(S),3(R),25-Trihydroxy-20(S)-9,10-seco-cholesta-5(Z),7(E),10,19-triene;</p>
    <p>1(S),3(R) -Dihydroxy-20(R)-(3-oxo-4-hydroxy-4-ethyl-1-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-methyl-18-(5-methyl-5-hydroxy-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-methyl-18-(4-ethyl-4-hydroxy-hexyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-methyl-18-(4-ethyl-4-hydroxy-hex-2-ynyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-methyl-18-(4-hydroxy-4-methylpentyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20-methyl-18-(4-hydroxy-4-methylpent)-2-yn-1-yloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S)3(R)-Dihydroxy-20-methyl-18-(3,1-hydroxy-1-methylethyl)phenylmethyloxy)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(1-methoxy-4-hydroxy-4-methyl-1-pentyl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene; isomer A;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(1-ethoxy4-hydroxy-4-methyl-1-pentyl) -9,10-seco-pregna-5(Z),7(E),10(19)-triene; isomer A;</p>
    <p>1(S),3(R),25-Trihydroxy-(20(S)-9,10-seco-cholesta-5(Z),7(E),10(19),23(E)-tetraene;</p>
    <p>1(S),3(R)-Dihydroxy-(20(S)-(6â²-hydroxy-6â²-methyl-4â²(E)-hepten-1â²yl)-9,10-seco-pregna-5(Z),7(E),10(19)-triene;</p>
    <p>1(S),3(R),22(S),25-Tetrahydroxy-20(R),9,10-seco-cholesta-5(Z),7(E),10(19),23(E)-tetraene;</p>
    <p>22(S)-Ethoxy-1(S)-3(R),25-trihydroxy-10(R)-,9,10-seco-cholesta-5(Z),7(E),10(1,23(E),-tetraene;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-(3-(1-hydroxy-1-methylethyl)phenoxymethyl)-9,10-secopregna-5(Z),7(E),10(19),16-tetraene or the corresponding 20(R) isomer;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-(3(1-hydroxy-1-methylethyl)phenylthiomethyl)-9,10-secopregna-5(Z),7(E),10(19),16-tetraene or the corresponding 20(R) isomer;</p>
    <p>1(S),3(R)-Dihydroxy-20(S)-(4-hydroxy-4-methylpent-1-yl)-9,10-secopregna-5(Z),7(E),10(19), 16-tetraene;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5-ethyl-5-hydroxyhept-1-yl)-9,10-secopregna-5(Z),7(E),10(19),16-tetraene or the corresponding 20(S) isomer;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(5-ethyl-5-hydroxyhepta-1(E),3(E)-dien-1-yl)-9,10-secopregna-5(Z),7(E),10(19),16-tetraene or the corresponding 20(S) isomer;</p>
    <p>1(S),3(R)-Dihydroxy-20(R)-(3cyclopropyl-3-hydroxyprop-1(E)-en-1-yl)-9,10-secopregna-5(Z),7(E),10(19),16-tetraene (24(S) isomer) or the corresponding 24(R) isomer; and</p>
    <p>1(S),3(R)-Dihydroxy-20(1,5-dihydroxy-5-ethyl-2-heptyn-1-yl)-9,10-secopregna-5(Z),7(E),10(19),17(20)Z-tetraene, both 22-isomers.</p>
    <p>As a second pharmacologically active component B it is preferred to use a group I, II or III topical steroid, more preferably a medium to weak acting steroid (groups I and II). Component B is preferably selected from the group consisting of Betamethasone (9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione) and esters thereof such as the 21-acetate, 17-adamantoate; 17-benzoate, 17-valerate, and 17,21-dipropionate; Alclomethasone and esters thereof such as the dipropionate; Clobetasole and esters thereof such as the propionate; Clobetasone and esters thereof such as the 17-butyrate; Desoximetasone; Diflucortolon and esters thereof, Diflorasone and esters thereof such as the diacetate; Fluocinonid; Flumetasone and esters thereof such as the pivalate; Fluocinolon and ethers and esters thereof such as the acetonide; Fluticasone and esters thereof such as the propionate; Fluprednidene and esters thereof such as the acetate; Halcinonide; Hydrocortisone and esters thereof such as the -17-butyrate; Mometasone and esters thereof such as the furoate; and Triamcinolon and ethers and esters thereof such as the acetonide; as well as mixtures thereof. More preferred examples of the corticosteroids are Betamethasone or esters thereof such as the 17-valerate or the 17,21-dipropionate, Clobetasole or esters thereof such as the propionate, Triamcinolon or ethers and/or thereof such as the acetonide or the acetonide-21-N-benzoyl-2-methyl-Î²-alaninate or the acetonide-21-(3,3-dimethylbutyrate), or Hydrocortisone or esters thereof such as the 17-butyrate.</p>
    <p>Moreover, the invention relates to a pharmaceutical compositions for dermal use which contain at least one vitamin D or vitamin D analogue and at least one corticosteroid and which exhibits a higher efficacy in the treatment of psoriasis and other inflammatory skin diseases in humans and other mammals than any of the pharmacologically active components used alone. Said efficacy is preferably measured as percentage change in PASI score in psoriasis and related skin diseases, such as sebo-psoriasis and seborrhoic dermatitis.</p>
    <p>PASI (Psoriasis Area and Severity Index) score assesses the extent and severity of the patient's psoriasis. The following formulae are used to calculate the PASI score:</p>
    <p>Arms 0.2(R+T+S)E=X</p>
    <p>Trunk 0.3(R+T+S)E=Y</p>
    <p>Legs 0.4(R+T+S)E=Z</p>
    <p>Where R=score for redness, T=score for thickness, S=score for scaliness, and E=score for extent where the score is assessed according to a scale from 0 to 4 as follows:</p>
    <p>0=no involvement, 1=&lt;10%, 2=10-29&amp;, 3=30-49%, and 4=50-69%. The sum of X+Y+Z gives the total PASI score which can range from 0 to 64.8.</p>
    <heading>DESCRIPTION OF THE DRAWINGS</heading> <p>FIG. 1 is a graphic illustration of the percentage change in PASI score obtained during 4 weeks of clinical trial where the efficacy of a preparation according to the invention containing calcipotriol hydrate (52.2 Î¼g/g) and betamethasone dipropionate (0.643 mg/g) is compared to that of a preparation in the same vehicle containing only calcipotriol hydrate (52.2 Î¼g/g) and a preparation in the same vehicle of betamethasone dipropionate (0.643 mg/g). FIG. 1 shows an efficacy of the preparation of the invention which by far exceeds the efficacy obtainable by the two single component preparations. The change in PASI score reflects in the group of patients treated with the preparation of the invention a success of treatment of psoriasis Fail hitherto unattainable by treatment with commercial preparations containing either calcipotriol or betamethasone, or by alternating treatment with such commercial preparations (cf. ) thus proving the advantage of having the two active components present in the same preparation. (EOT=end of treatment).</p>
    <p>FIG. 2 is a table showing the figures for percentage change in PASI score at each visit and end of treatment for the same clinical trial as described for FIG. <b>1</b>.</p>
    <p>FIG. 3 is a bar diagram showing percentage of responders as a result of investigators' assessment of overall efficacy at each visit and end of treatment in the same clinical trial as for FIG. <b>1</b>. Responders are defined as patients with marked improvement or clearance.</p>
    <p>FIG. 4 is a table showing the figures for percentage of responders as a result of investigators' assessment of overall efficacy at each visit and end of treatment, cf. FIG. 3, in the same clinical trial as for FIG. <b>1</b>.</p>
    <heading>TOPICAL FORMULATIONS</heading> <p>In a preferred embodiment the invention provides a topical pharmaceutical composition in the form of an ointment, a cream, a lotion, preferably a scalp lotion, a liniment or other spreadable liquid or semi liquid preparation which is, preferably, non-aqueous or in the form of an oil-in-water or water-in-oil emulsion. In one preferred embodiment, the composition of the invention is a mono-phase composition, i.e. a composition comprising a single solvent system, such as an ointment.</p>
    <p>In a further preferred embodiment the invention provides a non-aqueous pharmaceutical composition for dermal use, said composition comprising</p>
    <p>a first pharmacologically active component A consisting of at least one vitamin D analogue:</p>
    <p>a second pharmacologically active component B consisting of at least one corticosteroid;</p>
    <p>the difference between the optimum stability pH of a first pharmacologically active component A and the optimum stability pH of a second pharmacologically active component B being at least 1; and</p>
    <p>at least one solvent component C selected from the group consisting of:</p>
    <p>(i) compounds of the general formula R<sup>3</sup>(OCH<sub>2</sub>C(R<sup>1</sup>)H)<sub>x</sub>OR<sup>2 </sup>(I) wherein x is in the range of 2-60, R<sup>1 </sup>in each of the x units independently is H or CH<sub>3</sub>, R<sup>2 </sup>is straight chain or branched C<sub>1-20</sub>alkyl or benzoyl, and R<sup>3 </sup>is H or phenylcarbonyloxy;</p>
    <p>(ii) di-(straight or branched)-C<sub>4-10</sub>alkyl esters of C<sub>4</sub>-C<sub>8</sub>dicarboxylic acids;</p>
    <p>(iii) straight or branched C<sub>12-18</sub>-alkyl benzoates;</p>
    <p>(iv) straight or branched C<sub>2-4</sub>-alkyl esters of straight or branched C<sub>10-18</sub>-alkanoic or -alkenoic acids;</p>
    <p>(v) propylenglycol diesters with C<sub>8-14</sub>-alkanoic acids; and</p>
    <p>(vi) branched primary C<sub>18-24</sub>alkanols, and wherein components A and B are as defined above.</p>
    <p>It has been found that in such combination compositions containing a solvent component C, the active components can co-exist without degradation, despite their different pH/stability profiles. The tendencies of the active compounds to affect one another with regard to pH is minimised or eliminated.</p>
    <p>It is preferred that the maximum difference in optimum stability pH between the pharmacologically active compounds is at least 1.5, more preferred at least 2, in particular at least 2.5, more particularly at least 3, especially at least 4, such as at least 5.</p>
    <p>In the general formula (I) defined above, it is preferred that the factor x (which designates the number of the units within the parentheses) is in the range 4-50, more preferably 4-40, in particular 4-30, especially 5-25, more especially 10-20, such as about 15. It is further preferred that R<sup>1â</sup> is CH<sub>3</sub>.</p>
    <p>It is preferred that said component C is selected from compounds of the general formula H(OCH<sub>2</sub>C(R<sup>1</sup>)H)<sub>x</sub>OR<sup>2 </sup>(II) where R<sup>1</sup>, x, and R<sup>2 </sup>are as defined above, and mixtures thereof.</p>
    <p>As nor-limiting specific examples of the types (i)-(vi) of the solvent component C defined above may be mentioned the following, including trade names:</p>
    <p>Arlamol E (polyoxyethylene(15) stearyl ether);</p>
    <p>Arlamol DoA (diisooctyl ester of adipic acid);</p>
    <p>Arlasolve 200 (Polyoxyethylene-20-isohexadecyl ether);</p>
    <p>Eutanol G (2-octyldodecanol);</p>
    <p>Finsolv (Isostearyl benzoate);</p>
    <p>Finsolv P (polyoxypropylene-15-stearyl ether benzoate);</p>
    <p>Isopropylesters of straight or branched C<sub>10</sub>-C<sub>18</sub>alkanoic or alkenoic acids such as isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linolate and isopropyl monooleate;</p>
    <p>Miglyol 840 (Propylene glycol diester of caprylic and caprinic acid);</p>
    <p>DPPG (propylene glycol dipelagonate);</p>
    <p>Procetyl AWS (CH<sub>3</sub>(CH<sub>2</sub>)<sub>14</sub>CH<sub>2</sub>(OCH(CH<sub>3</sub>)CH<sub>2</sub>)<sub>5</sub>â(OCH<sub>2</sub>)<sub>20</sub>OH).</p>
    <p>The compositions of the present invention may be prepared in accordance with methods well known to the person skilled in the field of pharmacy. Thus, the non-aqueous compositions may be prepared by incorporating the components into a well known ointment or lotion base excipient such as white soft paraffin (also known as vaseline) or Plastibaseâ¢ (a base prepared from polyethylene (average MW about 21,000) and paraffin liquid) or ESMA-Pâ¢ (a microcrystalline wax). As an example, preparation of a composition according to the invention is typically performed by melting while soft paraffin, adding a solution (typically at a concentration in the range of 0.0005-2.5% w/w) of the vitamin D analog in the required amount of solvent component C, e.g. Arlamol E, followed by addition of a dispersion of the corticosteroid component B in paraffin oil, typically with a particle size of from 0.1 to 20 Î¼m, and then cooling the mixture. Typical content ranges of the various components in the finished composition according to the invention are 0.005 to 0.1% w/w of the corticosteroid component B, from 0.0001 to 0.025% w/w of the vitamin D analog component A, and from 1 to 20% w/w of the solvent component C, the remainder typically being primarily base excipient such as the abovementioned white soft paraffin and/or paraffin oil. The composition may also contain other commonly used additives such as antioxidants (e.g. Î±-tocopherol).</p>
    <p>The composition according to the invention provides the following therapeutic advantages in the treatment of skin diseases, such as psoriasis, sebo-psoriasis and related disorders, compared to the single compound therapy or combination therapy of the prior art:</p>
    <p>A clinical investigation has showed that treatment of psoriasis patients with a composition according to the invention comprising calcipotriol and betamethasone resulted in a faster onset of healing and a more effective healing of plaques than patients treated with only one of the active compounds.</p>
    <p>A composition combining a vitamin D analogue and a topical steroid provides synergy in the form of additional benefit to the patient apart from the direct therapeutic value of the active substances. It has been shown that the skin irritative side effects of a vitamin D analogue, such as calcipotriol, is alleviated by the simultaneous application of a steroid, such as betamethasone, onto psoriatic skin, an effect that is only attainable using a two-component or multi-component treatment regimen where a vitamin D analogue and a steroid cannot be applied simultaneously to affected skin due to incompatibility of the praparations. When both a vitamin D analogue and a topical steroid are used in a combination treatment of psoriasis it has hitherto been necessary to use separate applications, typically one in the morning and the other in the evening, making it impossible to obtain any synergistic effect of the two types of active compounds (cf. Ortonne, J. P., Nouv. Dermatol., 1994, 13(10), p. 746-751), or where a certain degree of synergistic effect, such as less skin irritation, has been reported for a two-component regiment (cf. Kragballe, K. et al. <i>Br J Dermatol </i>1998 Oct;139(4):649-54, and Ruzicka, T. et Lorenz, B. <i>Br J Dermatol </i>1998, 138(2), 254-58) a substantial proportion of psoriasis patients will not benefit due to non-compliance with the treatment regimen.</p>
    <p>Satisfactory medical treatment of skin disorders, such as psoriasis, can be attained in a shorter period of time using the composition according to the invention resulting in a reduction of steroid side effects, such as skin atrophy and rebound. Besides, it can be anticipated that even a milder acting steroid of group 1, such as hydrocortisone which is presently not administered for psoriasis treatment, will be efficient in reducing or even eliminating the skin irritation which often follows calcipotriol treatment.</p>
    <p>Thus, the tolerance of the treatment will be considerably improved due to reduction of side effects of the active compounds.</p>
    <p>Instructions for treatment will be simpler when a single preparation is needed resulting in improved compliance for the patient and the possibility of efficient treatment of a much larger population of psoriasis patients.</p>
    <p>Instructions for treatment will be simpler when a single preparation is needed resulting in improved safety for the patient.</p>
    <p>The invention also relates to a preferred pharmaceutical preparation according to the invention which is especially useful for the treatment of psoriatic skin diseases which are complicated by additional fungal infections, and which further contains an anti-fungal agent selected, e.g., from the group consisting of miconazol, clotrimazol, terbinafin, ciclopirox, bifonazol, nystatin, ketoconazol, econazol, and amorolfine.</p>
    <p>Preferably, the compositions according to the invention do not contain other therapeutically effective compounds selected from the group consisting of the xanthine derivatives pentoxifylline, propentofyllin, and torbafylline, or any other xanthine or xanthine derivative.</p>
    <p>The invention also relates to a method of treatment of psoriasis and related skin diseases comprising topically administering an effective amount of a composition according to the invention to a patient in need of such treatment. Said method preferably comprises topical administration once or twice daily of a medically sufficient dosage of said composition.</p>
    <p>The composition according to the invention preferably contains 0.001-5 mg/g or ml or more preferably 0.01-0.25 mg/g or ml of said component A and 0.05-0.1 mg/g or ml of said component B.</p>
    <p>The invention is further illustrated by the following, non-limiting examples.</p>
    <heading>EXAMPLE 1</heading> <heading>Ointment Containing Calcipotriol and Betamethasone Dipropionate</heading> <p>919.3 g of White Soft Paraffin is melted at 80Â° C. followed by cooling to 70Â° C. and maintaining that temperature. Thereafter, 52.2 mg Calcipotriol hydrate (50 mg Calcipotriol) is dissolved in 50 g Arlamol E (polyoxypropylene-15-stearyl ether) to form a solution (Solution 1). Solution 1 is then added slowly into the molten paraffin while stirring.</p>
    <p>Betamethasone (0.5 g, in the form of 0.643 g of its dipropionate) in particulate form (99%&lt;15 Î¼m) is dispersed in 30 g Paraffin Liquid to form Dispersion 1. Dispersion 1as well as 20 mg Î±-tocopherol are added to the Calcipotriol-containing paraffin mixture of while stirring, after which the mixture is cooled to below 30Â° C. to give a composition according to the invention with the following composition:</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="84pt" align="left"> </colspec> <colspec colname="2" colwidth="98pt" align="left"> </colspec> <colspec colname="3" colwidth="35pt" align="left"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">1 g of ointment contains:</td>
                <td class="description-td">Betamethasone</td>
                <td class="description-td">0.5 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">(as dipropionate 0.643 mg)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Calcipotriol</td>
                <td class="description-td">â50 Î¼g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">(as hydrate 52.2 Î¼g)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Paraffin, Liquid</td>
                <td class="description-td">â30 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Polyoxypropylene-15-Stearyl</td>
                <td class="description-td">â50 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Ether</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Î±-Tocopherol</td>
                <td class="description-td">â20 Î¼g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">White Soft Paraffin to make</td>
                <td class="description-td">ââ1 g</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>EXAMPLE 2</heading> <heading>Stability Test</heading> <p>The chemical stability of the two active components was tested after storage for 1 month at 40Â° C. and 3 months at 25Â° C. and 40Â° C., respectively. The quantitative content of Calcipotriol was determined by HPLC.</p>
    <p>The Calcipotriol was extracted from the preparation into a mixture of methanol and 0.01M diammonium hydrogenphosphate (70:30) and quantified under the following HPLC conditions: Column: about 125 mm Ã¸ 4 mm (i.d.) stainless steel column with LiChrospher RP-18, 5 Î¼m; mobile phase: acetonitrile-methanol-0.01 M aqueous ammonium phosphate pH 6 (20:50:30); flow: about 2 ml/min; detection: variable wavelength UV-detector set at 265 nm. Calcipotriol and the related substances were separated by the reverse phase HLPC-method described above; Column: Superspher RP-18, 4 Î¼m; Flow: 1.2 ml/min. The quantitative content of Betamethasone Dipropionate was determined by HLPC.</p>
    <p>The Betamethasone Dipropionate was extracted from the preparation into a mixture of acetonitrile:water (50:55) and quantified under the following HPLC conditions: Column: About 125 mm Ã¸ 4 mm (i.d.) stainless steel column packed with LiChrospher RP-18, 5 Î¼m. Mobile phase: Acetonitrile: water (50:55). Flow: 2 ml/min. Detection: Variable wavelength UV-detector set at 240 nm. The related substances besides betamethasone were determined by a reverse phase HLPC-method analogous to the above. Betamethasone: Determined as above with the exception of the mobile phase: Acetonitrile/methanol/0.05M buffer pH7 (25:5:70).</p>
    <p>The results are shown in the following Table 1.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="offset" colwidth="35pt" align="left"> </colspec> <colspec colname="1" colwidth="28pt" align="center"> </colspec> <colspec colname="2" colwidth="42pt" align="center"> </colspec> <colspec colname="3" colwidth="49pt" align="center"> </colspec> <colspec colname="4" colwidth="63pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" rowsep="1" class="description-td" colspan="5">TABLE 1</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Calcipotriol-</td>
                <td class="description-td"> </td>
                <td class="description-td">Betamethasone-</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Calci-</td>
                <td class="description-td">related</td>
                <td class="description-td">Betamethasone</td>
                <td class="description-td">related</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">potriol</td>
                <td class="description-td">substances</td>
                <td class="description-td">dipropionate</td>
                <td class="description-td">substances</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Î¼g/g</td>
                <td class="description-td">%</td>
                <td class="description-td">mg/g</td>
                <td class="description-td">%</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="1" colwidth="35pt" align="left"> </colspec> <colspec colname="2" colwidth="28pt" align="center"> </colspec> <colspec colname="3" colwidth="42pt" align="center"> </colspec> <colspec colname="4" colwidth="49pt" align="center"> </colspec> <colspec colname="5" colwidth="63pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Start</td>
                <td class="description-td">50.0</td>
                <td class="description-td">1.6</td>
                <td class="description-td">0.63</td>
                <td class="description-td">1.2</td>
              </tr> <tr class="description-tr"> <td class="description-td">25Â° C.</td>
              </tr> <tr class="description-tr"> <td class="description-td">3 months</td>
                <td class="description-td">50.5</td>
                <td class="description-td">1.4</td>
                <td class="description-td">0.64</td>
                <td class="description-td">0.2</td>
              </tr> <tr class="description-tr"> <td class="description-td">40Â° C.</td>
              </tr> <tr class="description-tr"> <td class="description-td">1 month</td>
                <td class="description-td">48.0</td>
                <td class="description-td">2.1</td>
                <td class="description-td">0.64</td>
                <td class="description-td">0.6</td>
              </tr> <tr class="description-tr"> <td class="description-td">3 months</td>
                <td class="description-td">49.7</td>
                <td class="description-td">1.8</td>
                <td class="description-td">0.64</td>
                <td class="description-td">0.2</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>It will be seen from Table 1 that both Calcipotriol and Betamethasone ester are very stable under the test conditions.</p>
    <p>The stability of Calcipotriol was compared to an similar ointment where propylene glycol was used as the solvent and lanolin used as an emulsifier. The composition of the comparison ointment was the same as the above with respect to Calcipotriol and Betamethasone dipropionate, as well as 10% w/w propylene glycol,10% w/w anhydrous lanolin and 80% w/w White Soft Paraffin. The comparison ointment was stored for 2.5 months at 5Â° C. and 40Â° C., respectively. Only the content of Calcipotriol-related substances was determined in the manner described above. The results are shown in Table 2.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 2</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Calcipotriol related substances %</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="56pt" align="left"> </colspec> <colspec colname="1" colwidth="84pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">â5Â° C.</td>
                <td class="description-td">20</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">40Â° C.</td>
                <td class="description-td">96</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>As it will be seen from the results, Calcipotriol is degraded almost completely in the comparison composition under the test conditions as opposed to a composition of the invention, where the Calcipotriol is retained with essentially no degradation.</p>
    <heading>EXAMPLE 3</heading> <heading>Medical Skin Lotion Comprising a Two Phase Solvent System</heading> <p>1 g contains:</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="168pt" align="left"> </colspec> <colspec colname="2" colwidth="35pt" align="left"> </colspec> <thead> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Betamethasone (As Dipropionate 0.643 mg)</td>
                <td class="description-td">â0.5 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Calcipotriol (as Hydrate 52.2 Î¼g)</td>
                <td class="description-td">â50 Î¼g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Disodium Phosphate Dihydrate</td>
                <td class="description-td">â2.5 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Diazolidinyl Urea</td>
                <td class="description-td">â3 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Polyoxypropylene-15-Stearyl Ether (ArlamolâÂ® E)</td>
                <td class="description-td">â50 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Isohexadecan (ArlamolâÂ® HD)</td>
                <td class="description-td">200 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Polyoxyethylene-2-Stearyl Ether (BrijâÂ® 72)</td>
                <td class="description-td">â30 mg</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Water, purified to make</td>
                <td class="description-td">â1 g</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>Procedure for the preparation of 1 kg of lotion:</p>
    <p>2.5 g Disodium Phosphate and 3 g Diazolidinyl Urea are dissolved in about 714 g water. The solution is heated to 60-70Â° C. to obtain the water phase. 30 g Polyoxyethylene-2-Stearyl Ether is melted together with 200 g Isohexadecan at 60-70Â° C. and a solution of 52.2 mg Calcipotriol Hydrate in 50 g Polyoxypropylene-15-Stearyl Ether is added to obtain the oil phase. The two phases are mixed during homogenisation, 643 mg Betamethasone Dipropionate is dispersed into the mixture, and the lotion is cooled during mixing to room temperature. The preparation is stable at 25Â° C. for &gt;14 days.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4569935">US4569935</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 9, 1983</td><td class="patent-data-table-td patent-date-value">Feb 11, 1986</td><td class="patent-data-table-td ">University Of Tennessee Research Corp.</td><td class="patent-data-table-td ">Topical treatment of psoriasis with imidazole antibiotics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4794106">US4794106</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 28, 1986</td><td class="patent-data-table-td patent-date-value">Dec 27, 1988</td><td class="patent-data-table-td ">Taisho Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Hydrocortisone butyrate propionate, higher paraffinic hydrocarbon, surfactant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4981845">US4981845</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 25, 1989</td><td class="patent-data-table-td patent-date-value">Jan 1, 1991</td><td class="patent-data-table-td ">Chesebrough Pond&#39;s U.S.A. Co., Division Of Conopco, Inc.</td><td class="patent-data-table-td ">Cosmetic composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5087620">US5087620</a></td><td class="patent-data-table-td patent-date-value">May 17, 1990</td><td class="patent-data-table-td patent-date-value">Feb 11, 1992</td><td class="patent-data-table-td ">Bristol-Myers Squibb Co.</td><td class="patent-data-table-td ">Controlled dermal penetration enhancement using imidazoles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5827520">US5827520</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 22, 1996</td><td class="patent-data-table-td patent-date-value">Oct 27, 1998</td><td class="patent-data-table-td ">L&#39;oreal</td><td class="patent-data-table-td ">Vehicle and composition containing this vehicle and a stabilized cosmetic or dermatological active substance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5854246">US5854246</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 25, 1995</td><td class="patent-data-table-td patent-date-value">Dec 29, 1998</td><td class="patent-data-table-td ">Janssen Pharmaceutica, N.V.</td><td class="patent-data-table-td ">Topical ketoconazole emulsions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5886038">US5886038</a></td><td class="patent-data-table-td patent-date-value">Mar 24, 1998</td><td class="patent-data-table-td patent-date-value">Mar 23, 1999</td><td class="patent-data-table-td ">Panda Pharmaceuticals, L.L.C.</td><td class="patent-data-table-td ">Topically administering to a human a composition having isopropyl myristate as the only active ingredient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5990100">US5990100</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 1998</td><td class="patent-data-table-td patent-date-value">Nov 23, 1999</td><td class="patent-data-table-td ">Panda Pharmaceuticals, L.L.C.</td><td class="patent-data-table-td ">Composition and method for treatment of psoriasis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0129003A2?cl=en">EP0129003A2</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 1984</td><td class="patent-data-table-td patent-date-value">Dec 27, 1984</td><td class="patent-data-table-td ">Yissum Research Development Company Of The Hebrew University Of Jerusalem</td><td class="patent-data-table-td ">Cosmetic and dermatological compositions containing 1-alpha-hydroxycholecalciferol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0544391A1?cl=en">EP0544391A1</a></td><td class="patent-data-table-td patent-date-value">Aug 19, 1992</td><td class="patent-data-table-td patent-date-value">Jun 2, 1993</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">Compositions for topical treatment of psoriasis and atopic dermatitis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1991012807A1?cl=en">WO1991012807A1</a></td><td class="patent-data-table-td patent-date-value">Feb 25, 1991</td><td class="patent-data-table-td patent-date-value">Sep 5, 1991</td><td class="patent-data-table-td ">Leo Pharm Prod Ltd</td><td class="patent-data-table-td ">Use of vitamin-d analogues in the treatment of acne</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994014453A1?cl=en">WO1994014453A1</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 1993</td><td class="patent-data-table-td patent-date-value">Jul 7, 1994</td><td class="patent-data-table-td ">Leo Pharm Prod Ltd</td><td class="patent-data-table-td ">Hydroxy vitamin d3 compounds for treating skin atrophy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994015912A1?cl=en">WO1994015912A1</a></td><td class="patent-data-table-td patent-date-value">Jan 7, 1994</td><td class="patent-data-table-td patent-date-value">Jul 21, 1994</td><td class="patent-data-table-td ">Leo Pharm Prod Ltd</td><td class="patent-data-table-td ">New crystalline form of a vitamin d analogue</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">"<a href='http://scholar.google.com/scholar?q="Database+STN+Intern.+File+Caplus+%5BOn+line%5D%3B+Glade+C+P+et+al%3A+Epidermal+cell+DNA+content+and+intermediate+filaments+keratin+10+and+vimentin+after+treatment+of"'>Database STN Intern. File Caplus [On line]; Glade C P et al: Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of</a>" retrieved from CAPLUS, accession No. 1996:599855. Database accession No. 125:266250 XP002900974 abstract * BR. J. Dermatol., vol. 135, No. 3, 1996, pp. 379-384.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bazek et al., Nouv. Dermatol., vol. 13, No. 10, pp. 746-751 (1994) (with English translation).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">CAPlus AN: 1985:27554 English abstract of Veverka, CS 214078, 1982.*</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Gennaro Remington's Pharmaceutical Sciences, 18th ed., p. 1310.*</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kragballe et al., British Journal of Dermatology, vol. 139, pp. 649-654 (1998).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Richards et al., J. Am. Acad Dermatol., vol. 41, No. 4, pp. 581-583 (Oct. 1999).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ruzick et al.., British Journal of Dermatology 1998; 139: 254-258.*</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ruzicka et al: "<a href='http://scholar.google.com/scholar?q="Comparison+of+calcipotriol+monotherapy+and+a+combination+of+calcipotriol+and+betamethasone+valerate+after+2+weeks%27treatment+with+calcipotriol+in+the+topical+therapy+of+psoriasis+vulgaris%3A+a+multicentre%2C+doucle-blind%2C+randomized+study"'>Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks'treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, doucle-blind, randomized study</a>" British Journal of Dermatology, vol. 138, 1998, pp. 254-258, XP002900975 pp. 257.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7507865">US7507865</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 28, 2007</td><td class="patent-data-table-td patent-date-value">Mar 24, 2009</td><td class="patent-data-table-td ">Laboratorios Vinas, S.A.</td><td class="patent-data-table-td ">reaction of anhydrous calcipotriol in water, in the absence of organic solvents; psoriasis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7713952">US7713952</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 9, 2007</td><td class="patent-data-table-td patent-date-value">May 11, 2010</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">2-methylene-19,26,27-trinor-(20S)-1Î±-hydroxyvitamin D3 and its uses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7741314">US7741314</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 25, 2007</td><td class="patent-data-table-td patent-date-value">Jun 22, 2010</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">anticarcinogenic agent; arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte; inhibiting adipocyte differentiation and stearoyl CoA desaturase (SCD-1) gene transcription; skin disorder, psoriasis, obesity, antiinflammatory agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8034788">US8034788</a></td><td class="patent-data-table-td patent-date-value">May 10, 2006</td><td class="patent-data-table-td patent-date-value">Oct 11, 2011</td><td class="patent-data-table-td ">Dermipsor Ltd.</td><td class="patent-data-table-td ">Composition and methods for skin care</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8114859">US8114859</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 25, 2007</td><td class="patent-data-table-td patent-date-value">Feb 14, 2012</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263580">US8263580</a></td><td class="patent-data-table-td patent-date-value">May 26, 2006</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Stiefel Research Australia Pty Ltd</td><td class="patent-data-table-td ">Vitamin formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8298515">US8298515</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2010</td><td class="patent-data-table-td patent-date-value">Oct 30, 2012</td><td class="patent-data-table-td ">Stiefel Research Australia Pty Ltd.</td><td class="patent-data-table-td ">Vitamin formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8404667">US8404667</a></td><td class="patent-data-table-td patent-date-value">Dec 28, 2007</td><td class="patent-data-table-td patent-date-value">Mar 26, 2013</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">2-methylene-19-nor-20(S)-1 alpha -hydroxy-bishomopregnacalciferol; 13-cis-retinoic acid activator; acne, psoriasis, ichthyosis, photoaging, photodamaged skin, skin cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8629128">US8629128</a></td><td class="patent-data-table-td patent-date-value">Sep 20, 2012</td><td class="patent-data-table-td patent-date-value">Jan 14, 2014</td><td class="patent-data-table-td ">Stiefel West Coast, Llc</td><td class="patent-data-table-td ">Vitamin formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8685381">US8685381</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 2011</td><td class="patent-data-table-td patent-date-value">Apr 1, 2014</td><td class="patent-data-table-td ">Joel Schlessinger</td><td class="patent-data-table-td ">Topical base and active agent-containing compositions, and methods for improving and treating skin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20080152596">US20080152596</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 20, 2007</td><td class="patent-data-table-td patent-date-value">Jun 26, 2008</td><td class="patent-data-table-td ">Foamix Ltd.</td><td class="patent-data-table-td ">Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20100093676">US20100093676</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 14, 2008</td><td class="patent-data-table-td patent-date-value">Apr 15, 2010</td><td class="patent-data-table-td ">Wheeler Derek A</td><td class="patent-data-table-td ">Polyaphron topical composition with vitamin d</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120046253">US20120046253</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 27, 2011</td><td class="patent-data-table-td patent-date-value">Feb 23, 2012</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">STABLE PHARMACOLOGICALLY ACTIVE COMPOSITIONS INCLUDING VITAMIN D CONTAINING AND CORTICOSTEROID COMPOUNDS WITH LOW pH COMPATIBILITY</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1917072A2?cl=en">EP1917072A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 26, 2006</td><td class="patent-data-table-td patent-date-value">May 7, 2008</td><td class="patent-data-table-td ">Stiefel Research Australia Pty Ltd</td><td class="patent-data-table-td ">Vitamin formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2056791A2?cl=en">EP2056791A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 29, 2007</td><td class="patent-data-table-td patent-date-value">May 13, 2009</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Pharmaceutical compositions including vitamin d and corticosteroid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006120682A2?cl=en">WO2006120682A2</a></td><td class="patent-data-table-td patent-date-value">May 10, 2006</td><td class="patent-data-table-td patent-date-value">Nov 16, 2006</td><td class="patent-data-table-td ">Dermipsor Ltd</td><td class="patent-data-table-td ">Compositions and methods for treating hyperproliferative epidermal diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007082533A1?cl=en">WO2007082533A1</a></td><td class="patent-data-table-td patent-date-value">May 8, 2006</td><td class="patent-data-table-td patent-date-value">Jul 26, 2007</td><td class="patent-data-table-td ">Leo Pharma As</td><td class="patent-data-table-td ">Isomerisation of pharmaceutical intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010129062A1?cl=en">WO2010129062A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 7, 2010</td><td class="patent-data-table-td patent-date-value">Nov 11, 2010</td><td class="patent-data-table-td ">Herbert Brinkman</td><td class="patent-data-table-td ">Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S484000">424/484</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S384000">514/384</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S167000">514/167</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S485000">424/485</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S486000">424/486</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S488000">424/488</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S178000">514/178</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S336000">514/336</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S487000">424/487</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047100000">A61K47/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K">A61K</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031573000">A61K31/573</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047320000">A61K47/32</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P">A61P</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0017060000">A61P17/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009060000">A61K9/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031410000">A61K31/41</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031440000">A61K31/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009140000">A61K9/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009100000">A61K9/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07C">C07C</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031590000">A61K31/59</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031560000">A61K31/56</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031580000">A61K31/58</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031593000">A61K31/593</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047140000">A61K47/14</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/0014">A61K9/0014</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/06">A61K47/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/573">A61K31/573</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/10">A61K47/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/56">A61K31/56</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/593">A61K31/593</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=DRVnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/59">A61K31/59</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K47/10</span>, <span class="nested-value">A61K9/00M3</span>, <span class="nested-value">A61K47/06</span>, <span class="nested-value">A61K31/59</span>, <span class="nested-value">A61K31/573</span>, <span class="nested-value">A61K31/593</span>, <span class="nested-value">A61K31/56</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Apr 1, 2014</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 28, 2014</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 3, 9, 10, 13, 15, 20 AND 22 ARE CANCELLED.CLAIMS 1, 4-5, 7-8, 11-12, 14, 17-19, 21 AND 23 ARE DETERMINED TO BE PATENTABLE AS AMENDED.CLAIMS 2, 6 AND 16, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE.NEW CLAIMS 24-80 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 22, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 31, 2007</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 26, 2007</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 5, 2006</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060717</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 22, 2001</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">LEO PHARMACEUTICAL PRODUCTS LTD. A/S, DENMARK</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DIDRIKSEN, ERIK;HOY, GERT;REEL/FRAME:012315/0869</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20011001</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">LEO PHARMACEUTICAL PRODUCTS LTD. A/S INDUSTRIPARKE</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DIDRIKSEN, ERIK /AR;REEL/FRAME:012315/0869</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_4ff636b3d23669b7103f3b3a3a18b4cd.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U3cH01kXMQUGc50FzTcqlGQ8PqLew\u0026id=DRVnBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U2sBGD_XJY_SXLCwzvt5TjQy36mcw\u0026id=DRVnBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U2TUDelxG7wEqS0nQF-Hgv55UKdMw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Vitamin_d_or_vitamin_d_analogue_a_cortic.pdf?id=DRVnBAABERAJ\u0026output=pdf\u0026sig=ACfU3U03G3kSgCgIo26Sfm6ivkkh97Jb4g"},"sample_url":"http://www.google.com/patents/reader?id=DRVnBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>